Atara Biotherapeutics, INC. (ATRA) — 8-K Filings

All 8-K filings from Atara Biotherapeutics, INC.. Browse 26 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (26)

Atara Biotherapeutics Reports Exit/Disposal Costs — Oct 7, 2025 Risk: medium
On October 6, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify doll
Atara Biotherapeutics Announces Executive and Director Changes — Sep 4, 2025 Risk: medium
Atara Biotherapeutics, Inc. announced on September 2, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure
Atara Biotherapeutics Files 8-K: Operations & Financial Update — Jul 14, 2025 Risk: low
On July 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns results of operations, financial condition, and other events. I
Atara Biotherapeutics Holds Special Stockholder Meeting — Jun 11, 2025 Risk: low
On June 10, 2025, Atara Biotherapeutics, Inc. filed an 8-K report indicating that it held a special meeting of stockholders on June 10, 2025. The primary purpos
Atara Biotherapeutics Files 8-K Report — May 16, 2025 Risk: low
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
Atara Biotherapeutics Files 8-K on Leadership and Compensation — May 15, 2025 Risk: medium
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
Atara Biotherapeutics Reports Exit/Disposal Costs — May 12, 2025 Risk: medium
On May 12, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify the exa
Atara Biotherapeutics Files 8-K — May 6, 2025 Risk: low
On May 5, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
Atara Biotherapeutics Enters Material Definitive Agreement — Apr 4, 2025 Risk: medium
On March 31, 2025, Atara Biotherapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, i
Atara Biotherapeutics Files 8-K: Director Changes & Officer Compensation Updates — Mar 31, 2025 Risk: medium
On March 25, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
Atara Biotherapeutics Files 8-K on Financials — Mar 7, 2025 Risk: low
On March 7, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Atara Biotherapeutics Reports Exit/Disposal Costs — Mar 3, 2025 Risk: medium
On March 3, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify dollar
Atara Biotherapeutics Files 8-K on Exit Costs — Jan 27, 2025 Risk: medium
On January 27, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns cost associated with exit or disposal activities and include
Atara Biotherapeutics Files 8-K — Jan 21, 2025 Risk: low
On January 21, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
Atara Biotherapeutics Files 8-K — Jan 16, 2025 Risk: low
On January 16, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
Atara Biotherapeutics Changes Fiscal Year End — Dec 23, 2024 Risk: low
Atara Biotherapeutics, Inc. filed an 8-K on December 23, 2024, reporting a change in its fiscal year end to December 31st. This filing does not appear to contai
Atara Biotherapeutics Announces Executive and Board Changes — Oct 15, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on October 14, 2024, changes in its executive team and board of directors. The filing details the departure of certain off
Atara Biotherapeutics Announces Board and Executive Changes — Sep 3, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on September 3, 2024, changes in its board of directors and executive compensation arrangements. The filing details the de
Atara Biotherapeutics Files 8-K Report — Jul 17, 2024 Risk: low
On July 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates
Atara Biotherapeutics Files 8-K: Rights, Bylaws, and Financials Updated — Jun 20, 2024 Risk: medium
On June 20, 2024, Atara Biotherapeutics, Inc. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also includ
Atara Biotherapeutics Files 8-K — Jun 17, 2024 Risk: low
On June 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
Atara Biotherapeutics Files 8-K for Security Holder Vote — Jun 11, 2024 Risk: low
On June 10, 2024, Atara Biotherapeutics, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not c
Atara Biotherapeutics Names New CEO, Board Changes — Mar 29, 2024 Risk: medium
Atara Biotherapeutics, Inc. announced on March 26, 2024, changes in its executive and director roles. Dr. Pascal Touchon has been appointed as the new Chief Exe
Atara Biotherapeutics Reports Executive Changes and Compensation Updates — Feb 23, 2024 Risk: medium
Atara Biotherapeutics, Inc. filed an 8-K on February 22, 2024, reporting on the departure of directors or certain officers, election of directors, appointment o
Atara Biotherapeutics Reports Material Agreement, Nasdaq Listing Issues — Jan 9, 2024
Atara Biotherapeutics, Inc. filed an 8-K on January 8, 2024, to report an "Entry into a Material Definitive Agreement" and a "Notice of Delisting or Failure to
Atara Biotherapeutics 8-K: Exit Costs, Officer Comp Changes — Jan 8, 2024
Atara Biotherapeutics, Inc. filed an 8-K on January 8, 2024, reporting on costs associated with exit or disposal activities, changes in officers' compensatory a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX